268600 — Cellivery Therapeutics Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,512 | 2,074 | 762 | 3,872 | 23,158 |
Cost of Revenue | |||||
Gross Profit | 1,517 | -1,902 | -723 | 70.6 | -269 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4,192 | 16,658 | 18,373 | 31,921 | 93,411 |
Operating Profit | 320 | -14,584 | -17,612 | -28,048 | -70,253 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6,651 | -19,577 | -17,937 | -29,682 | -75,018 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6,698 | -19,650 | -17,248 | -28,069 | -75,159 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -6,698 | -19,650 | -17,248 | -28,069 | -75,159 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -6,698 | -19,650 | -17,248 | -28,069 | -75,159 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -465 | -632 | -535 | -834 | -2,900 |
Dividends per Share |